Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 30.97%1.01B | 19.27%263.1M | 26.16%241.6M | 45.01%271.9M | 36.05%234M | 73.86%771.6M | 48.45%220.6M | 77.48%191.5M | 78.06%187.5M | 109.76%172M |
Operating revenue | 30.97%1.01B | 19.27%263.1M | 26.16%241.6M | 45.01%271.9M | 36.05%234M | 73.86%771.6M | 48.45%220.6M | 77.48%191.5M | 78.06%187.5M | 109.76%172M |
Cost of revenue | 11.75%131.2M | 15.91%35.7M | 4.61%31.8M | 13.93%31.9M | 12.77%31.8M | 0.77%117.4M | 8.83%30.8M | 4.11%30.4M | -5.08%28M | -4.41%28.2M |
Gross profit | 34.42%879.4M | 19.81%227.4M | 30.23%209.8M | 50.47%240M | 40.61%202.2M | 99.88%654.2M | 57.77%189.8M | 104.70%161.1M | 110.42%159.5M | 173.90%143.8M |
Operating expense | 25.02%505.6M | 15.46%126.2M | 29.67%126.3M | 35.97%135.7M | 19.92%117.4M | 34.04%404.4M | 15.78%109.3M | 44.51%97.4M | 32.89%99.8M | 51.08%97.9M |
Selling and administrative expenses | 9.09%49.2M | 12.96%12.2M | 3.45%12M | 12.62%11.6M | 8.06%13.4M | 22.55%45.1M | -1.82%10.8M | 65.71%11.6M | 7.29%10.3M | 34.78%12.4M |
-General and administrative expense | 9.09%49.2M | 12.96%12.2M | 3.45%12M | 12.62%11.6M | 8.06%13.4M | 22.55%45.1M | -1.82%10.8M | 65.71%11.6M | 7.29%10.3M | 34.78%12.4M |
Operating profit | 49.64%373.8M | 25.71%101.2M | 31.08%83.5M | 74.71%104.3M | 84.75%84.8M | 875.78%249.8M | 210.81%80.5M | 463.72%63.7M | 8,428.57%59.7M | 473.17%45.9M |
Net non-operating interest income expense | -23.84%-232.7M | -20.85%-62.6M | -20.59%-57.4M | -19.61%-55.5M | -32.30%-55.7M | -11.25%-187.9M | -15.63%-51.8M | 8.64%-47.6M | -25.75%-46.4M | -20.29%-42.1M |
Non-operating interest income | 30.61%6.4M | 42.86%1M | 1,900.00%2M | 52.94%2.6M | -37.50%1.5M | -9.26%4.9M | 0.00%700K | -87.50%100K | -56.41%1.7M | --2.4M |
Non-operating interest expense | 33.65%211.7M | 29.71%57.2M | 29.92%50.8M | 28.65%49.4M | 26.09%46.4M | 26.32%158.4M | 34.04%44.1M | 12.36%39.1M | 25.90%38.4M | 35.29%36.8M |
Total other finance cost | -20.35%27.4M | -23.81%6.4M | 0.00%8.6M | -10.31%8.7M | 40.26%10.8M | -29.65%34.4M | -33.33%8.4M | -52.49%8.6M | -5.83%9.7M | -1.28%7.7M |
Other net income (expense) | 86.21%-800K | 71.88%-2.7M | 25.00%-900K | -344.44%-2.2M | -14.63%3.5M | 95.58%-5.8M | -2,500.00%-9.6M | 87.50%-1.2M | 100.73%900K | 412.50%4.1M |
Gain on sale of security | ---- | ---- | 120.83%500K | 103.13%100K | -231.25%-2.1M | -211.11%-2.8M | -7.69%1.2M | -20.00%-2.4M | ---3.2M | 633.33%1.6M |
Earnings from equity interest | -124.49%-1.2M | 0.00%-2.5M | -245.45%-1.6M | -164.10%-2.5M | 125.00%5.4M | 308.33%4.9M | -278.57%-2.5M | 650.00%1.1M | 454.55%3.9M | 118.18%2.4M |
Special income (charges) | 105.06%400K | 97.59%-200K | 100.00%200K | 0.00%200K | 100.00%200K | 94.08%-7.9M | -260.87%-8.3M | 101.35%100K | 100.16%200K | --100K |
-Less:Impairment of capital assets | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
-Less:Other special charges | ---- | ---- | ---- | ---- | ---- | 44.07%8.5M | ---- | ---- | ---- | ---- |
-Gain on sale of property,plant,equipment | -33.33%400K | -200.00%-200K | 100.00%200K | 0.00%200K | 100.00%200K | -85.71%600K | -94.44%200K | 200.00%100K | -71.43%200K | --100K |
Income before tax | 150.09%140.3M | 87.96%35.9M | 69.13%25.2M | 228.17%46.6M | 312.66%32.6M | 120.44%56.1M | 203.24%19.1M | 129.56%14.9M | 108.93%14.2M | 116.99%7.9M |
Income tax | 71.18%58.2M | 203.23%9.6M | 6.16%15.5M | 11.19%14.9M | 18.95%18.2M | 84.78%34M | -432.14%-9.3M | 224.44%14.6M | 112.70%13.4M | 218.75%15.3M |
Net income | 271.49%82.1M | -7.39%26.3M | 3,133.33%9.7M | 3,862.50%31.7M | 294.59%14.4M | 107.55%22.1M | 233.33%28.4M | 100.55%300K | 100.48%800K | 85.58%-7.4M |
Net income continuous Operations | 271.49%82.1M | -7.39%26.3M | 3,133.33%9.7M | 3,862.50%31.7M | 294.59%14.4M | 107.55%22.1M | 233.33%28.4M | 100.55%300K | 100.48%800K | 85.58%-7.4M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 271.49%82.1M | -7.39%26.3M | 3,133.33%9.7M | 3,862.50%31.7M | 294.59%14.4M | 107.55%22.1M | 233.33%28.4M | 100.55%300K | 100.48%800K | 85.58%-7.4M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 271.49%82.1M | -7.39%26.3M | 3,133.33%9.7M | 3,862.50%31.7M | 294.59%14.4M | 107.55%22.1M | 233.33%28.4M | 100.55%300K | 100.48%800K | 85.58%-7.4M |
Basic earnings per share | 266.67%0.33 | 0.00%0.11 | 3,176.00%0.04 | 3,877.97%0.13 | 300.00%0.06 | 105.49%0.09 | 175.00%0.11 | 100.41%0.0012 | 100.30%0.0033 | 91.43%-0.03 |
Diluted earnings per share | 255.56%0.32 | -9.09%0.1 | 3,236.11%0.04 | 3,633.67%0.12 | 300.00%0.06 | 105.49%0.09 | 175.00%0.11 | 100.40%0.0012 | 100.29%0.0032 | 91.43%-0.03 |
Dividend per share | 440.00%0.27 | -60.00%0.02 | 0.1 | 0.1 | 0.05 | 0.05 | 0.05 | |||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |